Influence of Obesity and Type 2 Diabetes on Calcium Handling by Skeletal Muscle: Spotlight on the Sarcoplasmic Reticulum and Mitochondria

Hiroaki Eshima*

Department of International Tourism, Nagasaki International University, Nagasaki, Japan

Obesity and diabetes have been shown to interfere with energy metabolism and cause peripheral insulin resistance in skeletal muscle. However, recent studies have focused on the effect metabolic insult has on the loss of muscle size, strength, and physical function. Contractile dysfunction has been linked to impaired intracellular Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_i\)) regulation. In skeletal muscle, [Ca\(^{2+}\)]\(_i\) homeostasis is highly regulated by Ca\(^{2+}\) transport across the sarcolemma/plasma membrane, the golgi apparatus, sarcoplasmic reticulum (SR), and mitochondria. Particularly, the SR and or mitochondria play an important role in the fine-tuning of this metabolic process. Recent studies showed that obesity and insulin resistance are associated with interactions between the SR and mitochondrial networks (the dynamic tubular reticulum formed by mitochondria), suggesting that metabolic disorders alter Ca\(^{2+}\) handling by these organelles. These interactions are facilitated by specific membrane proteins, including ion channels. This review considers the impact of metabolic disorders, such as obesity and type 2 diabetes, on the regulation of [Ca\(^{2+}\)]\(_i\) in skeletal muscle. It also discusses the mechanisms by which this occurs, focusing chiefly on the SR and mitochondria networks. A deeper understanding of the effect of metabolic disorders on calcium handling might be useful for therapeutic strategies.

Keywords: sarcoplasmic reticulum, mitochondria, calcium, obesity, diabetes, skeletal muscle

INTRODUCTION

Obesity due to overeating and lack of exercise has become one of the major burdens of modern societies and is associated with many comorbidities, including type 2 diabetes mellitus (T2DM). Skeletal muscle is important for maintaining healthy body composition, physical function, and locomotion. Obesity is likely to cause a decrease in muscle mass and to lower muscle strength, which is associated with decreased mobility (Freedman et al., 2002). Previous studies have shown decreased muscle strength is observed in obese and T2DM patients (Park et al., 2006; Maffioletti et al., 2007). Consistent with these findings, recent studies using animal models confirmed that obesity and diabetes lead to decreased muscle contractile force normalized to muscle mass and decrease in muscle performance (Eshima et al., 2017b; Hurst et al., 2019).
However, an understanding of the mechanism for dysfunction of muscle contraction in obesity and T2DM has not been fully elucidated.

Transient elevation of intracellular Ca\textsuperscript{2+} concentration ([Ca\textsuperscript{2+}]i) is necessary for the initiation of tension development in skeletal muscle tissue (Allen et al., 2008). Dysfunction of muscle contraction in metabolic disease may depend on the impaired capacity for Ca\textsuperscript{2+} release and reuptake by the sarcoplasmic reticulum (SR; Westerblad et al., 2010). These features include decreased SR calcium release and or decreased SR calcium reuptake (Bruton et al., 2002; Bayley et al., 2016). We recently demonstrated Ca\textsuperscript{2+} regulatory impairments during muscle contraction in metabolic disease using the db/db mouse, a common model of obesity associated with T2DM (Eshima et al., 2019). Similar findings were seen in diet-induced obese mice (Eshima et al., 2020). On the other hand, type 1 diabetes mellitus (T1DM) affects [Ca\textsuperscript{2+}], independent of SR (Eshima et al., 2013, 2015). In this regard, recent studies suggest that mitochondria play a major role in the [Ca\textsuperscript{2+}], buffering with evidence for increased mitochondrial Ca\textsuperscript{2+} concentration ([Ca\textsuperscript{2+}]mito) during contractions in skeletal muscle (Shkryl and Shirokova, 2006; Ainbinder et al., 2015; Eshima et al., 2017a). Previous studies have shown the [Ca\textsuperscript{2+}]mito increases during electrical stimulation-induced contractions in skeletal muscle in vitro, suggesting that mitochondria are involved in the regulation of [Ca\textsuperscript{2+}], (Aydin et al., 2009; Rossi et al., 2011; Yamada et al., 2012). Consistent with this, mitochondrial Ca\textsuperscript{2+} uptake is a key supporter of excitation-contraction coupling in skeletal myotubes (Eisner et al., 2014). Indeed, altered [Ca\textsuperscript{2+}]mito is a common characteristic of some skeletal muscle myopathies (Debattisti et al., 2019; Favaro et al., 2019), suggesting that diabetic myopathy may also display elevated [Ca\textsuperscript{2+}]mito. This review considers the impact of obesity and diabetes on calcium handling by skeletal muscle, focusing on the SR and mitochondria. We propose that interactions between these organelles in skeletal muscles of obese and T2DM animals and patients alter calcium handling by skeletal muscles (see Figure 1).

### OBESITY AND TYPE 2 DIABETES ALTER CA\textsuperscript{2+} HANDLING IN SKELETAL MUSCLE

Ca\textsuperscript{2+} is a ubiquitous intracellular messenger that can regulate different cellular processes in living tissue (Berridge et al., 2016). In particular, it is well known that elevated [Ca\textsuperscript{2+}], and subsequent Ca\textsuperscript{2+} signaling directly regulate cellular metabolism in various tissues. By contrast, obesity has been shown to impair Ca\textsuperscript{2+} homeostasis in adipose, cardiac, B-cell, and liver (Dong et al., 2006; Park et al., 2010; Tong et al., 2016; Wright et al., 2017). Therefore, certain aspects of Ca\textsuperscript{2+} homeostasis in skeletal muscle may also be compromised in obesity and T2DM. Previous findings related to alteration in SR or mitochondrial Ca\textsuperscript{2+} handling by obesity and type 2 diabetes are summarized in Table 1. Bruton et al. demonstrated that ob/ob mice (genetic-induced obesity model) impaired Ca\textsuperscript{2+} handling in skeletal muscle fibers (Bruton et al., 2002). Recently, we demonstrated electrically stimulated Ca\textsuperscript{2+} peak levels were reduced by HFD feeding. Indeed, Ca\textsuperscript{2+} peak levels during the ryanodine receptor (RyR) agonist stimulation decrease in this model (Eshima et al., 2020). Consistent with this, db/db mice (an obese type 2 diabetes model) displayed impaired contractile force and reduced SR Ca\textsuperscript{2+}-ATPase (SERCA) pump expression (Bayley et al., 2016). Similarly, our study demonstrated a substantial degree of impairment in [Ca\textsuperscript{2+}], homeostasis in skeletal muscle of db/db mice (Eshima et al., 2019). Muscle contractile force and [Ca\textsuperscript{2+}], levels were both lower during electrical stimulation in this model, suggesting that decreased Ca\textsuperscript{2+} release may contribute to skeletal muscle contractile dysfunction in obese type 2 diabetic rodent models. In addition, Ca\textsuperscript{2+} release induced by the caffeine was decreased in db/db mice. Interestingly, dysfunction of Ca\textsuperscript{2+} release and contractile force was improved by endurance of exercise training in db/db mice. This study also found a consistent reduction in sarcalumenin, which is a Ca\textsuperscript{2+}-binding protein localized in the SR of the intracellular Ca\textsuperscript{2+} store in the skeletal muscles of these mice. This protein decreases in aging animals (O’Connell et al., 2008; Andersson et al., 2011). Collectively, it is expected that exercise intervention may increase the Ca\textsuperscript{2+} store content and improve calcium handling and contractile dysfunction associated with diabetic myopathy (Ferreira et al., 2010a).

### IMPACT OF OBESITY AND TYPE 2 DIABETES ON SARCOPLASMIC RETICULUM AND MITOCHONDRIAL RETICULUM

#### Sarcoplasmic Reticulum

**Ryanodine Receptor**

In skeletal muscle, the increases in [Ca\textsuperscript{2+}], are initiated by sarcocemmal and transverse tubule depolarization, triggering Ca\textsuperscript{2+} release from the SR via the RyR. Previous studies demonstrated that T1DM impaired Ca\textsuperscript{2+} release from the SR and decreased RyR protein contents (Eshima et al., 2013, 2015). Similar to T1DM, RyR protein content was decreased in db/db mice (Eshima et al., 2019). By contrast, no differences in the RyR protein content between HFD-induced obese mice and mice fed a normal diet (Eshima et al., 2017b; Gamu et al., 2019). On the other hand, oxidation of RyR has been implicated in Ca\textsuperscript{2+} leakage from the SR that causes muscle...
weakness in aged mice (Andersson et al., 2011). Consistent with this finding, Holloway and colleagues demonstrated that the nitrosylated tyrosine residues on RyRs was increased in HFD-induced obese rats, suggesting that Ca\(^{2+}\) leakage from RyR is regulated by reactive oxygen species (ROS; Jain et al., 2014). Ceramides, a family of lipid molecules composed of sphingosine and fatty acid, have been implicated in the induction of oxidative stress in skeletal muscle (Nikolova-Karakashian and Reid, 2011). In murine C2C12 myotubes, direct exposure to ceramide increased ROS and exogenous ceramide depressed diaphragm force production in mice. This weakness was prevented by antioxidant N-acetylcysteine treatment (Ferreira et al., 2010b). Interestingly, sphingosine blocks Ca\(^{2+}\) release from RyR and reduces the activity of channels reconstituted into planar lipid bilayers (Sabbadini et al., 1999; Sharma et al., 2000). This suggests that lipid mediators may play important roles in calcium kinetics. Indeed, exogenous sphingolipids and accumulation of ceramide in muscle depresses Ca\(^{2+}\) sensitivity of the contractile apparatus (Ferreira et al., 2012). HFD feeding increased muscle ceramides and induced glucose intolerance in mice (Frangioudakis et al., 2010). This provides evidence to support the hypothesis that obesity alters lipid species composition, particularly sphingolipids, and causes impairments in Ca\(^{2+}\) release capacity via RyR dysfunction.

**SR Ca\(^{2+}\)-ATPase**

Following muscle contraction, elevated [Ca\(^{2+}\)], rapidly decreases due to Ca\(^{2+}\) taken up by the SR and other intracellular organelles and returns almost immediately to basal resting levels via the activity of SR Ca\(^{2+}\)-ATPase (SERCA). Most of the studies addressing calcium signaling have been focused on this protein which has a significant influence on skeletal muscle metabolism. A previous study demonstrates reduced SERCA content in db/db mouse (Bayley et al., 2016). In contrast, previous studies have shown genetic obese rodent models displayed no changes in SERCA protein expression levels independent of diabetes (Jain et al., 2014; Eshima et al., 2019). Indeed, many studies have shown that HFD-induced obese rodents displayed no changes in SERCA activity and protein content (Ial et al., 2012; Fajardo et al., 2017; Eshima et al., 2017b; Gamu et al., 2019). Phospholipid composition plays a major role in determining membrane fluidity, and HFD feeding is known to alter phospholipid species abundance in mice (Montgomery et al., 2017). A reduction in phosphatidylethanolamine (PE) has been associated with decreased SERCA activity (Funai et al., 2016). A recent study demonstrates the absence of phosphatidylethanolamine N-methyltransferase (PEMT) promotes an increase in metabolic rate and protects from diet-induced obesity, potentially due to decreasing SERCA efficiency in skeletal muscle. However, this lack of PE methyltransferase also causes muscle weakness (Verkerke et al., 2019). In humans, recent studies utilizing muscle biopsies obtained from obese and T2DM patients demonstrate SERCA expression levels were increased compared to muscle from healthy participants (Chae et al., 2018; Gancheva et al., 2019). These data suggest certain aspects of the Ca\(^{2+}\) uptake into the SR are upregulated in skeletal muscle of patients with obesity and T2DM patients. Therefore, fundamental questions regarding muscle Ca\(^{2+}\) buffering associated with obesity remain to be more fully addressed. It may also be insightful to consider relevant organelles other than the SR in order to resolve the mechanistic basis for Ca\(^{2+}\) buffering alterations in obese skeletal muscle.

**Mitochondrial Networks**

Mitochondria are the organelles responsible for ATP production by oxidative phosphorylation. Mitochondria are in a dynamic state of fusion and division with respect to other mitochondria forming dynamic tubular structures called mitochondrial networks. Mitochondrial fragmentation may be associated with metabolic disorders (Fealy et al., 2021). A previous study showed that mitochondrial-associated endoplasmic reticulum membrane (MAM) integrity, VDAC1-inositol 1,4,5-trisphosphate receptor type1 (IP3R1) interactions are decreased in obese and T2DM patients, suggesting that metabolic disorders alter Ca\(^{2+}\) handling by these organelles (Tubbs et al., 2018). Indeed, recent evidence suggests that MAMs contribute to obesity and insulin resistance (Townsend et al., 2020). The mitochondrial networks are regulated by molecular structures in the mitochondrial membranes as indicated below.

**Voltage-Dependent Anion Channel**

Voltage-dependent anion channel (VDAC) is expressed on the outer mitochondrial membrane (OMM) and regulates mitochondrial oxidative phosphorylation. A previous study has shown decreased VDAC proteins and other mitochondrial related proteins in T2DM patients (Moller et al., 2017). VDAC overexpression affects the interaction between SR and mitochondria and enhances [Ca\(^{2+}\)]\(_{\text{mito}}\) in vitro (Rapizzi et al., 2002). These data suggest mitochondrial dysfunction might contribute to the impaired [Ca\(^{2+}\)], regulation in obesity and T2DM.

**Mitofusin**

Mitofusin (Mfn) participates in the fusion of the mitochondrial outer membranes of two adjacent mitochondria and may contribute to Ca\(^{2+}\) uptake into the mitochondria (Santel and Fuller, 2001). A previous study demonstrated Mfn2 knockdown decreased in [Ca\(^{2+}\)]\(_{\text{mito}}\) after muscle contraction in mouse skeletal muscle (Anbinder et al., 2015). Many studies have shown that Mfn is implicated in obesity and T2DM [see reviews (Zorzano et al., 2009; Fealy et al., 2018)]. Multiple studies have shown that obese rodent models display decreased Mfn2 in skeletal muscle, but there is no direct evidence of Mfn2 involvement in [Ca\(^{2+}\)]\(_{\text{mito}}\) regulation (Bach et al., 2003; Kong et al., 2013; Liu et al., 2014; Li et al., 2018). In addition, SR-mitochondria interactions are reduced in obesity and T2DM in vivo and in vitro. This suggests the metabolic disease may influence the interactions between these organelles (Tubbs et al., 2018). SR-mitochondria interaction is also required for insulin action as seen by decreases in insulin signaling with dysfunction in organelle interaction. Indeed, silencing Mfn2 attenuates increased mitochondrial Ca\(^{2+}\) uptake induced by insulin action in skeletal muscle. 
While direct evidence to support such claims is still lacking, these observations support the hypothesis that obesity and T2DM may contribute to dysfunction of $\left[\text{Ca}^{2+}\right]_{\text{m}}$ regulation.

**TABLE 1 | Intracellular calcium handling alterations in obese and type 2 diabetic skeletal muscle.**

| Model                     | Methods                                      | Assessment                                      | Change   | References                        |
|---------------------------|----------------------------------------------|-------------------------------------------------|----------|-----------------------------------|
| **Human**                 |                                              |                                                 |          |                                   |
| T2DM                      | Proteomes data analysis                      | SERCA1a                                         | ↑ or →   | Zemel et al., 1990; Agi et al., 2015 |
|                           | Transcriptome analysis                        | SRCA1a                                          | ↑ or →   | Jain et al., 2014                 |
|                           | VDAC                                          | Mn2                                             | ↓        | Bach et al., 2003                 |
| Obesity and T2DM          | Proteomes data analysis                      | SERCA2                                          | →        | Kugler et al., 2020               |
|                           | WB                                            | Mfn2                                            | ↓        | Bach et al., 2005                 |
|                           | RT-cPCR                                       | MAM integrity                                   | ↓        | Tubos et al., 2018                |
| Severe Obesity            | RNA sequencing and WB                         | SERCA1a, RyR1, SLN                              | ↑        | Paran et al., 2015                |
|                           | WB                                            | SERCA2                                          | →        | Moller et al., 2017               |
|                           | RT-cPCR                                       | Mfn2                                            | ↓        | Mfn2                              |
| Rodent                    |                                              |                                                 |          |                                   |
| Obese Zucker rats         | Absorption spectrophotometer                 | Intracellular $\left[\text{Ca}^{2+}\right]$ content | ↑ or →   | Fajardo et al., 2017             |
|                           | WB                                            | SERCA1a                                         | →        | Jheng et al., 2012                |
|                           | Northern blotting and WB                     | Mn2                                             | ↓        | Tubos et al., 2018                |
| HFD rats                  | SR fractions                                  | SERCA activity                                  | →        | Kom et al., 2013; Leduc-Gaudet et al., 2018 |
|                           | WB                                            | S-nitrosylation of the RyR                      | ↑        | Jain et al., 2014                 |
|                           | WB                                            | Mn2                                             | ↓ or →   | Kong et al., 2013; Leduc-Gaudet et al., 2018 |
| db/ob mice                | [Ca$^{2+}$] flux                              | $\left[\text{Ca}^{2+}\right]$ transient        | ↓        | Brunton et al., 2002             |
|                           | Chemical quench technique                    | Calcium uptake rate                             | →        | Fraser and Trayhurn, 1983         |
|                           | WB                                            | Mfn2                                            | ↓        | Jheng et al., 2012                |
|                           | In situ proximity ligation assay              | MAM integrity                                   | ↓        | Tubos et al., 2018                |
| db/db mice                | $\text{Ca}^{2+}$ steady-state rate            | SERCA activity                                  | ↓        | Bayley et al., 2016               |
|                           | WB                                            | RyR                                             | ↓        | Eshima et al., 2020               |
|                           | WB                                            | SERCA1a, DHPR, CSQ                              | →        | Jaque-Fernandez et al., 2020      |
| HFD mice                  | [Ca$^{2+}$] flux                              | $\left[\text{Ca}^{2+}\right]$ transient        | ↓        | Eshima et al., 2020               |
|                           | WB                                            | SERCA1a, SLN                                    | →        | Ciaipia et al., 2015              |
|                           | WB                                            | SERCA and CSQ                                   | ↓        | Eshima et al., 2017a              |
|                           | WB                                            | RyR and DHPR                                    | →        | Gamu et al., 2019                 |
|                           | SR fractions                                  | Phospholamban, SLN                              | →        | Funai et al., 2016                |
|                           | WB                                            | SERCA activity                                  | →        | Jheng et al., 2012; Liu et al., 2014; Li et al., 2018 |
|                           | Isolated mitochondria                         | Mfn2                                            | ↓        | Tai et al., 2014                  |
|                           | In situ proximity ligation assay              | Calcium retention capacity                      | ↓        | Tubos et al., 2018                |
|                           |                                               | MAM integrity                                   | ↓        |                                   |

CSQ, Calsequestrin; DHPR, Dihydropyridine Receptor; HFD, High-Fat Diet; RyR, Ryanodine receptor; SR, Sarcoplasmic reticulum; SERCA, SR $\text{Ca}^{2+}$-ATPase; T2DM, Type 2 diabetes mellitus; SLN, Sarcolipin; MAM, Mitochondria-Associated Endoplasmic Reticulum Membranes; MCU, Mitochondrial Calcium uniporter; Mfn, Mito Fusin; VDAC, Voltage Gated-Dependent Anion Channel; WB, Western blotting; RT-cPCR, Reverse Transcription and Competitive Polymerase Chain Reaction.

muscle cells (Del Campo et al., 2014). While direct evidence to support such claims is still lacking, these observations support the hypothesis that obesity and T2DM may contribute to dysfunction of $\left[\text{Ca}^{2+}\right]_{\text{m}}$ regulation.

**Mitochondrial Ca$^{2+}$ Uniporters**

The inner mitochondrial membranes of the mitochondria (IMM) contain mitochondrial Ca$^{2+}$ uptake-related proteins, called the mitochondrial Ca$^{2+}$ uniporters (MCU; Baughman et al., 2011).
The MCUs are regulated by mitochondrial Ca$^{2+}$ uptake 1 (MICU1), MICU2, and mitochondrial calcium uniporter regulator 1 (MCUR1), which binds Ca$^{2+}$ with high affinity and promotes uptake by mitochondria (Mammucari et al., 2016). Overexpressing MCU increases the mitochondrial size and causes muscle hypertrophy (Barclay et al., 2007; Mammucari et al., 2015). In contrast, other studies have shown the opposite alteration patterns in mitochondrial calcium uniporter related proteins in T2DM and upregulation of other proteins related to Ca$^{2+}$ transporter/homeostasis (Hwang et al., 2010; Chae et al., 2018). In heart muscle from individuals with T1DM, impaired mitochondrial Ca$^{2+}$ uptake is significantly improved by MCU restoration (Suarez et al., 2018). A previous study demonstrated that the mitochondrial calcium retention capacity is reduced in diet-induced obese mice, suggesting that dysregulation of MCU components is associated with insulin resistance (Taddeo et al., 2014). Collectively, this evidence suggests the possibility of a heretofore unappreciated role for [Ca$^{2+}$]$_{mito}$ regulation in the function of obese and diabetic muscle.

**CONCLUSION**

The present review addressed how obesity and T2DM influence Ca$^{2+}$ handling in skeletal muscle. Recent findings from studies in rodents demonstrated that genetic- and diet-induced obesity has detrimental effects on Ca$^{2+}$ handling. As shown in Figure 1, this observation may be associated with impaired SR Ca$^{2+}$ release and mitochondrial Ca$^{2+}$ uptake. These dysfunctions may be explained at least in part by a decrease in RyR content (or oxidation), a decrease in VDAC, mitofusin, and MCU in diabetic and obese skeletal muscle. These mechanisms are likely to be responsible for the muscle weakness that occurs as a result of obesity and T2DM and may prove useful for defining the optimal therapeutic strategies. Previous studies showed that patients with malignant hyperthermia have altered SR Ca$^{2+}$ release and impaired glucose tolerance (Altamirano et al., 2019; Bojko et al., 2021), suggesting that calcium handling is associated with glucose metabolism. Although mitochondrial calcium uniporter influences on systemic...
metabolism (Gherardi et al., 2019), the effect of mitochondrial Ca\(^{2+}\) uptake on metabolic disorders has not been fully clarified. Future studies will allow us to determine potential physiological mechanisms involving the SR and mitochondrial networks that are responsible for the impairment of Ca\(^{2+}\) homeostasis in skeletal muscle under conditions of metabolic disease.

**AUTHOR CONTRIBUTIONS**

HE drafted the manuscript, prepared a figure, edited, and revised the manuscript and approved the final version of manuscript.

**REFERENCES**

Agil, A., Elmahalawly, E. K., Rodriguez-Ferrer, J. M., Adem, A., Bastaki, S. M., Al-Abbadi, I., et al. (2015). Melatonin increases intracellular calcium in the liver, muscle, white adipose tissues and pancreas of diabetic obese rats. *Food Funct.*, 6, 2671–2678. doi: 10.1039/C5FO00950F

Ainbinder, A., Boncompagni, S., Protasi, E., and Dirksen, R. T. (2015). Role of Mitofusin-2 in mitochondrial localization and calcium uptake in skeletal muscle. *Cell Calcium* 57, 14–24. doi: 10.1016/j.ceca.2014.11.002

Allen, D. G., Lamb, G. D., and Westerblad, H. (2008). Skeletal muscle fatigue: cellular mechanisms. *Physiol. Rev.* 88, 287–332. doi: 10.1152/physrev.00015.2007

Altamirano, F., Rizzi, S., Ibarra Moreno, C. A., Kraeva, N., Uryash, A., Allen, P. D., et al. (2019). Is malignant hyperthermia associated with hyperglycaemia? *Br. J. Anaesth.* 122, e3–e5. doi: 10.1016/j.bja.2018.09.014

Andersson, D. C., Betzenhauser, M. J., Reiken, S., Meli, A. C., Umanskaya, A., Xie, W., et al. (2011). Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. *Cell Metab.* 14, 196–207. doi: 10.1016/j.cmet.2011.05.014

Aydin, J., Andersson, D. C., Hanninen, S. L., Wredenberg, A., Tavi, P., Park, C. B., et al. (2009). Increased mitochondrial Ca\(^{2+}\) uptake and decreased sarcoplasmic reticulum Ca\(^{2+}\) in mitochondrial myopathy. *Hum. Mol. Genet.* 18, 278–288. doi: 10.1093/hmg/ddn355

Bach, D., Naon, D., Pich, S., Soriano, F. X., Vega, N., Rieusset, J., et al. (2005). Expression of Mfn2, the Charcot-Marie-tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. *Diabetes* 54, 2685–2693. doi: 10.2337/diabetes.54.9.2685

Bach, D., Pich, S., Soriano, F. X., Vega, N., Baumgartner, B., Oriola, J., et al. (2003). Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. *J. Biol. Chem.* 278, 17190–17197. doi: 10.1074/jbc.M212754200

Bal, N. C., Maurya, S. K., Sopariwala, D. H., Sahoo, S. K., Gupta, S. C., Shaikh, S. A., et al. (2012). Sarcolipin is a newly identified regulator of mitochondrial metabolism. *Regul. Integr. Comp. Physiol.* 3, 31–41. doi: 10.1152/regint.00015.2012

Bayley, J. S., Pedersen, T. H., and Nielsen, O. B. (2016). Skeletal muscle dysfunction in the db/db mouse model of type 2 diabetes. *Muscle Nerve* 54, 460–468. doi: 10.1002/mus.25064

Berridge, M. J., Bootman, M. D., and Roderick, H. L. (2003). Calcium signalling: dynamics, homeostasis and remodelling. *Nat. Rev. Mol. Cell Biol.* 4, 517–529. doi: 10.1038/nrm1155

Bojko, B., Vasiljevic, T., Boyaci, E., Roszkowska, A., Kraeva, N., Ibarra Moreno, C. A., et al. (2021). Untargeted metabolomics profiling of skeletal muscle samples from malignant hyperthermia susceptible patients. *Can. J. Anaesth.* 68, 761–772. doi: 10.1007/s12306-020-01895-y

Bruton, J. D., Katz, A., Lannergren, J., Abbate, F., and Westerblad, H. (2002). Regulation of myoplasmic ca(2+) in genetically obese (Ob/Ob) mouse single skeletal muscle fibres. *Pflugers Arch.* 449, 692–699. doi: 10.1007/s00424-002-0882-1

Chae, S., Kim, S. J., Do Koo, Y., Lee, J. H., Kim, H., Ahn, B. Y., et al. (2018). A mitochondrially encoded proteome profile indicative of type 2 diabetes mellitus in skeletal muscles. *Exp. Mol. Med.* 50, 1–14. doi: 10.1038/s12276-018-0154-6

Capitae, J., Van Den Berg, S. A., Houten, S. M., Nicolay, K., Van Dijk, K. W., and Jenesen, J. A. (2015). Fiber-type-specific sensitivities and phenotypic adaptations to dietary fat overload differentially impact fast- versus slow-twitch muscle contractile function in C57BL/6J mice. *J. Nutr. Biochem.* 26, 155–164. doi: 10.1016/j.jnutbio.2014.09.014

Debattisti, V., Horn, A., Singh, R., Seifert, E. I., Hogarth, M. W., Mazala, D. A., et al. (2019). Dysregulation of mitochondrial ca(2+) uptake and sarcolemna repair underlie muscle weakness and wasting in patients and mice lacking MICU1. *Cell Rep.* 29:e1276. doi: 10.1016/j.celrep.2019.09.063

Del Campo, A., Parra, V., Vásquez-Trincado, C., Gutierrez, T., Morales, P. E., Lopez-Crisostoto, C., et al. (2014). Mitochondrial fragmentation impairs insulin-dependent glucose uptake by modulating Akt activity through mitochondrial Ca2+ uptake. *Am. J. Physiol. Endocrinol. Metab.* 306, E1–E13. doi: 10.1152/ajpendo.00146.2013

Dong, F., Zhang, X., Yang, X., Esberg, L. B., Yang, H., Zhang, Z., et al. (2006). Impaired cardiac contractile function in ventricular myocytes from leptin-deficient Ob/Ob obese mice. *J. Endocrinol.* 188, 25–36. doi: 10.1677/joe.0.06241

Esner, V., Lenaers, G., and Hajnoczyk, G. (2014). Mitochondrial fusion is frequent in skeletal muscle and supports excitation-contraction coupling. *J. Cell Biol.* 205, 179–195. doi: 10.1083/jcb.201312066

Eshima, H., Miura, S., Senou, N., Hatakeyama, K., Poole, D. C., and Kano, Y. (2012a). Improved skeletal muscle ca(2+) regulation in vivo following contractions in mice overexpressing PGC-1alpha. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 312, R1017–R1028. doi: 10.1152/ajpregu.00332.2017

Eshima, H., Poole, D. C., and Kano, Y. (2015). In vivo Ca2+ buffering capacity and microvascular oxygen pressures following muscle contractions in diabetic rat skeletal muscles: fibre-type specific effects. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 309, R128–R137. doi: 10.1152/ajpregu.00444.2015

Eshima, H., Tamura, Y., Kakehi, S., Kakigi, R., Hashimoto, R., Funai, K., et al. (2020). A chronic high-fat diet exacerbates contractile dysfunction with impaired intracellular ca(2+) release capacity in the skeletal muscle of aged mice. *J. Appl. Physiol.* 128, 1153–1162. doi: 10.1152/japplphysiol.00530.2019

Eshima, H., Tamura, Y., Kakehi, S., Kurebayashi, N., Murayama, T., Nakamura, K., et al. (2017b). Long-term, but not short-term high-fat diet induces fiber composition changes and impaired contractile force in mouse fast-twitch skeletal muscle. *Physiol. Rep.* 5:e13250. doi: 10.14814/phy2.13250

Eshima, H., Tamura, Y., Kakehi, S., Kurebayashi, N., Murayama, T., et al. (2019). Dysfunction of muscle contraction with impaired intracellular calcium(2+) handling in skeletal muscle and the effect of exercise training in male db/db mice. *J. Appl. Physiol.* 126, 170–182. doi: 10.1152/japplphysiol.0048.2018

Eshima, H., Tanaka, Y., Sonobe, T., Inagaki, T., Nakajima, T., Poole, D. C., et al. (2013). In vivo imaging of intracellular Ca2+ after muscle contractions and direct Ca2+ injection in rat skeletal muscle in diabetes. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 305, R610–R618. doi: 10.1152/ajpregu.00023.2013

**FUNDING**

This article was supported by the KAKENHI from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

**ACKNOWLEDGMENTS**

I gratefully acknowledge Justin Shahtout at University of Utah for helpful comments on the manuscript. A figure was created with Biorender.com.
Santel, A., and Fuller, M. T. (2001). Control of mitochondrial morphology by a human mitofusin. *J. Cell Sci.* 114, 867–874. doi: 10.1242/jcs.114.5.867

Sharma, C., Smith, T., Li, S., Schroepfer, G. J., Jr., and Needleman, D. H. (2000). Inhibition of Ca²⁺ release channel (ryanodine receptor) activity by sphingolipid bases: mechanism of action. *Chem. Phys. Lipids* 104, 1–11. doi: 10.1016/S0009-3084(99)00106-1

Shkryl, V. M., and Shirokova, N. (2006). Transfer and tunneling of Ca²⁺ from sarcoplasmic reticulum to mitochondria in skeletal muscle. *J. Biol. Chem.* 281, 1547–1554. doi: 10.1074/jbc.M505024200

Sharma, C., Smith, T., Li, S., Schroepfer, G. J. Jr., and Needleman, D. H. (2000). Inhibition of Ca²⁺ release channel (ryanodine receptor) activity by sphingolipid bases: mechanism of action. *Chem. Phys. Lipids* 104, 1–11. doi: 10.1016/S0009-3084(99)00106-1

Shkryl, V. M., and Shirokova, N. (2006). Transfer and tunneling of Ca²⁺ from sarcoplasmic reticulum to mitochondria in skeletal muscle. *J. Biol. Chem.* 281, 1547–1554. doi: 10.1074/jbc.M505024200

Suarez, J., Cividini, F., Scott, B. T., Lehmann, K., Diaz-Juarez, J., Diemer, T., et al. (2018). Restoring mitochondrial calcium uniporter expression in diabetic mouse heart improves mitochondrial calcium handling and cardiac function. *J. Biol. Chem.* 293, 8182–8195. doi: 10.1074/jbc.RA118.002066

Taddeo, E. P., Laker, R. C., Breen, D. S., Akhtar, Y. N., Kenwood, B. M., Liao, J. A., et al. (2014). Opening of the mitochondrial permeability transition pore links mitochondrial dysfunction to insulin resistance in skeletal muscle. *Mol Metab* 3, 124–134. doi: 10.1016/j.molmet.2013.11.003

Tong, X., Kono, T., Anderson-Baucum, E. K., Yamamoto, W., Gilon, P., Lebeche, D., et al. (2016). SERCA2 deficiency impairs pancreatic beta-cell function in response to diet-induced obesity. *Diabetes* 65, 3039–3052. doi: 10.2337/db16-0084

Townsend, L. K., Brunetta, H. S., and Mori, M. A. S. (2020). Mitochondria-associated ER membranes in glucose homeostasis and insulin resistance. *Am. J. Physiol. Endocrinol. Metab.* 319, E1053–E1060. doi: 10.1152/ajpendo.00271.2020

Tubbs, E., Chanon, S., Robert, M., Bendridi, N., Bidaux, G., Chauvin, M. A., et al. (2018). Disruption of mitochondria-associated endoplasmic reticulum membrane (MAM) integrity contributes to muscle insulin resistance in mice and humans. *Diabetes* 67, 636–650. doi: 10.2337/db17-0316

Verkerke, A. R. P., Ferrara, P. J., Lin, C. T., Johnson, J. M., Ryan, T. E., Maschek, J. A., et al. (2019). Phospholipid methylation regulates muscle metabolic rate through ca(2+) transport efficiency. *Nat. Metab.* 1, 876–885. doi: 10.1038/s42255-019-0111-2

Westerblad, H., Place, N., and Yamada, T. (2010). Mechanisms of skeletal muscle weakness. *Adv. Exp. Med. Biol.* 682, 279–296. doi: 10.1007/978-1-4419-6366-6_16

Wright, L. E., Vecellio Reane, D., Milan, G., Terrin, A., Di Bello, G., Belligoli, A., et al. (2017). Increased mitochondrial calcium uniporter in adipocytes underlies mitochondrial alterations associated with insulin resistance. *Am. J. Physiol. Endocrinol. Metab.* 313, E641–E650. doi: 10.1152/ajpendo.00143.2016

Yamada, T., Ivarsson, N., Hernandez, A., Fahlstrom, A., Cheng, A. J., Zhang, S. J., et al. (2012). Impaired mitochondrial respiration and decreased fatigue resistance followed by severe muscle weakness in skeletal muscle of mitochondrial DNA mutator mice. *J. Physiol.* 590, 6187–6197. doi: 10.1113/jphysiol.2012.240077

Zemel, M. B., Sowers, J. R., Shehin, S., Walsh, M. F., and Levy, J. (1990). Impaired calcium metabolism associated with hypertension in Zucker obese rats. *Metabolism* 39, 704–708. doi: 10.1016/0026-0495(90)90104-K

Zorzano, A., Llais, M., and Palacin, M. (2009). Mitochondrial dynamics as a bridge between mitochondrial dysfunction and insulin resistance. *Arch. Physiol. Biochem.* 115, 1–12. doi: 10.1080/13813450802676335

**Conflict of Interest:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021 Eshima. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**